Objectives Interleukin-1 receptor-associated kinase (IRAK)-M suppresses Toll-like receptor (TLR)-mediated activation of innate immunity during infection. A similar role was hypothesised for IRAK-M in autoimmunity. Methods Irak-m-defi cient mice were crossed with autoimmune C57BL/6-lpr/lpr mice and detailed phenotype analysis was performed. Results Irak-m defi ciency converted the mild autoimmune phenotype of C57BL/6-lpr/lpr mice into a massive lymphoproliferative syndrome with lethal autoimmune lung disease and lupus nephritis. Irak-m defi ciency induced a number of interferon-related genes, cytokines and plasma cell survival factors in spleen cells of these mice. Irak-m-defi cient C57BL/6-lpr/lpr mice showed expansion of autoreactive T cells, dysfunctional regulatory T cells and plasma cells which was associated with increased lupus autoantibody production. TLR7 antagonism almost completely abrogated this phenotype consistent with IRAK-M-mediated suppression of TLR7 signalling in vitro. Conclusions These data identify a previously unknown function of IRAK-M-namely, suppression of TLR7-mediated autoimmunity-and mutant IRAK-M as a previously unknown genetic risk for murine SLE.
INTRODUCTION
Autoimmunity means loss of tolerance against selfantigens by, for example, the presence of autoantibodies. Transient autoimmunity is common, but whether or not it manifests as autoimmune tissue injury depends on the signals and genetic factors that regulate the expansion of autoreactive lymphocytes. 1 2 For example, in systemic lupus erythematosus (SLE), loss of tolerance affects ubiqitous nuclear autoantigens and can result in a spectrum of clinical manifestations ranging from mild skin rashes and arthralgia to severe infl ammation of the kidney, lungs or brain. 3 SLE develops when gene variants promote the exposure of nuclear particles to the immune system-for example, defects in apoptosis, in opsonisation of dying cells, in phagocytosis or in extracellular nuclease activity. 4 Other genetic risk factors affect immune recognition of self-nucleic acids by Toll-like receptors (TLR), subsequent danger signalling and the production of type I interferons, 5 a process that also enhances the presentation of nuclear autoantigens and the subsequent expansion of autoreactive lymphocytes. 6 A third class of genetic factors promote tissue infl ammation and damage. 4 Combinations of genetic polymorphisms in either weak or potent susceptibility genes account for the variable disease onset and clinical manifestation patterns in human SLE. For example, a genome-wide association study in 1311 patients with SLE and 3340 control subjects identifi ed HLA, STAT4, IRF5, BLK and ITGAM-ITGAX as variant genes with a particularly strong association with SLE. 7 Murine studies have been used to identify the relative importance of single genes for SLE. For example, potent susceptibility genes such as transforming growth factor β 1 (TGF-β 1 ), DNase1, Lyn, Fas or C1q were identifi ed because they were suffi cient to cause lupus-like autoimmunity in the absence of additional predisposing factors. 8 -13 Lupus risk genes are less potent when they require a second genetic factor to trigger SLE-that is, genes such as SLE1, TLR7, TLR9 or SIGIRR. 14 -17 Weaker disease modifi er genes such as interleukin (IL)-10 or IL-27R enhance SLE only together with other susceptibility genes, for example, being provided by the specifi c autoimmune genetic background of MRL mice. 18 19 The interleukin-1 receptor-associated kinases (IRAK) have important roles in innate immunity because they regulate signal transduction of the IL-1R and the TLRs. For example, the MyD88 signalling pathway requires IRAK-4 to phosphorylate TRAF6, 20 which is inhibited by another member of the IRAK family, IRAK-M, in cells of the monocyte/macrophage lineage. 21 22 IRAK-M induction contributes to endotoxin tolerance 21 22 and sepsisinduced 23 or tumour-associated immunosuppression. 24 IRAK-M also limits infection-associated immunopathology 25 and prevents osteoporosis by suppressing osteoclast differentiation. 26 Consistent with these immunosuppressive effects, loss of function mutations in the human IRAK-M gene are associated with inappropriate immunopathology such as in asthma. 27 Interestingly, genome-wide association studies located as yet unknown lupus risk factors to the IRAK-M gene locus at chromosome 12p14. 7 We therefore hypothesised a role for IRAK-M beyond the control of microbial defence in the suppression of inadequate TLR signalling in antigen-presenting cells (APCs), a recently discovered pathomechanism of autoimmunity. 6 We approached this hypothesis by characterising the phenotype of Irak-m -defi cient C57BL/6 lpr/lpr (B6 lpr ) mice in which the lpr mutation fosters autoantibody production and mild autoimmune tissue injury. 8 
METHODS

Animal studies
Irak-m -defi cient mice were generated as previously described 21 and back-crossed to the C57BL/6 strain (B6; Charles River Laboratories, Sulzbach Germany) to the F10 generation. B6 lpr/Irak-m-/-and B6 lpr mice (Charles River) were mated to generate B6 lpr/Irak-m-/+ mice which were then mated among each other to generate B6 lpr/Irak-m+/+ and B6 lpr/Irak-m-/-mice. Littermates were used for all experimental procedures. In each individual mouse the genotype was assured by PCR. Mice were housed in groups of fi ve in sterile fi lter top cages with a 12 h dark/light cycle and unlimited access to autoclaved food and water. Power calculations performed on the primary endpoint (the 'lupus nephritis activity index') determined a group size of 17. One cohort of mice was killed by cervical dislocation at 24 weeks of age and one cohort was followed until 52 weeks of age. Other groups of B6 lpr and B6 lpr/Irak-m-/-mice were treated by intraperitoneal injection either with saline or with the TLR7 blocking phosphothioate oligodeoxyribonucleotide IRS 661 (5′-TGCTTGCAAGC TTGCAA-GCA-3′; TIB Molbiol, Berlin, Germany) at a dose of 40 μg on alternate days from weeks 13-24 of age as described elsewhere. 28 IRS 661 prevents the activation of dendritic cells and B cells of lpr mice upon exposure to TLR7 agonists, 28 29 and the dose selected was previously shown to be effective in vivo. 28 All experimental procedures were performed according to the German animal care and ethics legislation and had been approved by the local government authorities.
In vitro experiments
Spleen monocytes from wild-type and Irak-m -defi cient mice were kept in RPMI medium with 10% fetal calf serum and 1% penicillin/streptomycin. 5×10 6 cells in 12-well plates were stimulated for 24 h with the TLR4 agonist ultrapure lipopolysaccharide (LPS, 1 μg/ml; Invitrogen, Karlsruhe, Germany), the TLR7 agonist imiquimod (1 μg/ml; Sequoia Research Products Ltd, Oxford, UK) or the TLR9 agonist CpG-DNA (1 μg/ml; Invitrogen). Y12 and snRNP (Arotec, Wellington, New Zealand) were used in concentrations of 5 μg/ml and 10 μg/ml, respectively. IL-6 and tumour necrosis factor α (TNFα) concentrations were determined in cell supernatants by ELISA following the manufacturer's protocols (OptEiA; BD Biosciences, Heidelberg, Germany).
Flow cytometry
Anti-mouse CD3, CD4, CD8 and CD25 (BD Pharmingen, Heidelberg, Germany) antibodies were used to detect CD3+CD4−CD8-double negative T cells and CD4+CD25+/ Foxp3 regulatory T cell (Treg) populations in the spleen. CD11c was stained to identify plasmacytoid and myeloid dendritic cells and their activation was assessed by co-staining for CD40 and MHC II (BD Pharmingen). Dendritic cell subtypes were identifi ed using CD4 and CD8a co-stained with CD11c. Anti-mouse B220, CD21, CD23, IgD and IgM antibodies (BD Pharmingen) were used to identify B cell subsets from a spleen single cell suspension. Anti-mouse κ light chain and CD138 (BD Pharmingen) were used to identify plasma cells. F4/80, CD11b and MHC II (BD Pharmingen) were used to identify macrophage activation. Activated B cells were identifi ed with co-staining of B220, CD19 and CD69 (BD Pharmingen) and T cell activation was identifi ed with CD69 co-stained with T cell markers shown above. An Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen) was used to identify apoptotic cells. Respective isotype antibodies were used to demonstrate specifi c staining of cell subpopulations. Cell counting beads (Invitrogen) were used for cell counting by fl uorescence-activated cell sorting (FACS).
T cell proliferation assays
CD4+CD25+ Treg cells and CD4+CD25 neg T effector (Teff) cells from the spleen were purifi ed by two-step magnetic cell sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). The remaining cells were used as APCs. CD4+CD25 neg Teff cells (7.5×10 4 cells) were activated with anti-CD3 antibody (0.1 μg/ml, clone 500A2, BD Biosciences) in the presence of APCs (2×10 4 cells) and increasing numbers of CD4+CD25+ Tregs (5-40 × 10 3 cells) as described previously. 30 The cells were then co-cultured for 60 h in the presence of BrdU (Sigma-Aldrich, Steinheim, Germany). BrdU incorporation into CD4+FoxP3 neg Teff cells was detected by fl ow cytometry using a Regulatory T Cell Staining Kit (eBioscience, San Diego, California, USA). After incubation with Pacifi c Blue-labelled FoxP3 antibody, the cells were fi xed with 1% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), incubated with DNase I (Sigma-Aldrich) and stained with antiBrdU-FITC antibody (Invitrogen). Analysis was performed using a FACSCanto II fl ow cytometer (BD Biosciences) and FlowJo software (TreeStar, Ashland, Oregon, USA).
Evaluation of autoimmune tissue injury
Spleens were frozen in liquid nitrogen and cut in 7 μm sections. Slides were fi xed in acetone at 4°C for 10 min at room temperature, placed in PBS for 5 min and blocked with 5% goat serum in PBS for 20 min. The following primary antibodies were used for staining (all from BD): anti-mCD11c (clone HL3, 1:50), antimCD3e (clone 500A2, 1:50) and anti-mCD19 (clone1D3, 1:50). Secondary antibodies used for staining were (all from Invitrogen): Alexa Fluor 647 goat anti-rat IgG (1:200), Alexa Fluor 488 goat anti-hamster IgG (1:200) and streptavidin Alexa Fluor 555 conjugate (1:200). Sections were mounted with Vectashield containing 4′,6-diamidino-2-phenylindole (DAPI). The slides were scanned using an Olympus BX 61 microscope and recorded via CellP software; the scans underwent digital morphometry using Adobe Photoshop. Lungs and kidneys from all mice were fi xed in 10% buffered formalin, processed and embedded in paraffi n. Two μm sections for periodic acid-Schiff (PAS) staining were prepared following routine protocols. The severity of the renal lesions was graded using the activity and chronicity indices for human lupus nephritis as described previously. 31 Serum IL-12 levels were determined by ELISA following the manufacturer's protocol (OptEiA; BD Biosciences).
Autoantibody analysis
Serum antibody levels were determined by ELISA as described elsewhere. 17 Anti-dsDNA antibodies: NUNC maxisorp ELISA plates were coated with poly-L-lysine (Trevigen, Gaithersburg, Maryland, USA) and mouse embryonic stem cell dsDNA. After incubation with mouse serum, dsDNA-specifi c IgG, IgG 1 , IgG 2a/c , IgG 2b , IgG 3 and serum IgG levels were detected by ELISA (Bethyl Labs, Montgomery, Texas, USA).
Critidiae luciliae assay: 1:50 diluted serum was applied to fi xed C luciliae slides (BioRad Laboratories, Redmond, Washington, USA). Binding to C luciliae kinetoplast was detected with FITC-conjugated goat anti-mIgG (1:1000, Invitrogen, Eugene, Oregon USA). DAPI staining (Vector Laboratories, Burlingame, California, USA) allowed co-localisation with kinetoplast dsDNA. For quantitation of kinetoplast staining intensity a semiquantitative score from 0 to 3 was used.
Anti-Sm: NUNC maxisorp ELISA plates were coated with Smith (Sm) antigen (Immunovision, Springdale, Arkansas, USA). The Sm IgG (Y12) antibody (GeneTex, San Antonio, Texas, USA) was used for standard. A horseradish peroxidaseconjugated goat anti-mouse IgG (Rockland, Gilbertsville, Pennsylvania, USA) was used for detection. The same procedure was followed for anti-SmRNP, anti-nucleosome and anti-Sm but ELISA plates were coated with Sm-RNP (Immunovision) or nucleosomes (USB Corporation, Cleveland, hio USA), respectively.
Rheumatoid factor: ELISA plates were coated with 10 μg/ml rabbit IgG (Jackson Immunoresearch, West Grove, Pennsylvania, USA) overnight at 4°C. Serum samples were diluted 1:100; C57BL/6 10-week mouse serum was used as negative control. HRP-conjugated anti-mouse IgG was used as a secondary antibody.
Real-time quantitative (TaqMan) RT-PCR
Real-time (RT)-PCR was performed on mRNA from cells purifi ed from spleen by two-step magnetic cell sorting (Miltenyi Biotec) as previously described. 17 The SYBR Green Dye detection system was used for quantitative RT-PCR on Light Cycler 480 (Roche, Mannheim, Germany). Gene-specifi c primers (300 nM; Metabion, Martinsried, Germany) were used (see table 2 in online supplement). Controls consisting of ddH 2 O were negative for target and housekeeper genes.
Statistical analysis
One-way ANOVA followed by a post hoc Bonferroni test was used for multiple comparisons using GraphPad Prism Version 4.03. Single groups were compared by the unpaired two-tailed Student t test. Data were expressed as mean±SEM. Survival curves were compared by Kaplan-Meier analysis using logrank two-tailed testing. Statistical signifi cance was assumed at p<0.05.
RESULTS
IRAK-M suppresses TLR7 and TLR9 signalling
IRAK-M is known to suppress TLR4 signalling at the kinase level, 21 which is shared by other TLRs. 32 We therefore hypothesised that IRAK-M would also suppress TLR7 and TLR9 signalling. Spleen monocytes were prepared from wild-type and Irak-m -defi cient mice and stimulated with the TLR4 agonist LPS, the TLR7 agonist imiquimod and the TLR9 agonist CpG-DNA, or with immune complexes (Y12snRNP). All three TLR agonists induced the production of TNFα, IL-6 and expression of interferon α (IFNα) within 24 h in wild-type splenocytes, but Irak-m -defi cient cells produced much more of these cytokines ( fi gure 1A ). Thus, IRAK-M suppresses TLR7 and TLR9 signalling in addition to TLR4 signalling.
IRAK-M is induced in spleens and suppresses lymphoproliferation in B6 lpr mice.
We fi rst carefully evaluated Irak-m -defi cient B6 mice for signs of spontaneous autoimmunity but found no difference in lupus autoantibodies, serum cytokines and spleen immune cell numbers or state of activation from wild-type B6 mice up to 12 months of age (see table 1 in online supplement). Next we generated Irak-m -defi cient B6 lpr mice. The phenotype of homozygous B6 lpr mice is introduced only by a single lupus susceptibility gene ( lpr ) which impairs Fas-induced apoptosis of autoreactive B and T cells. 8 Because B6 lpr mice produce antinuclear autoantibodies and minor immune complex glomerulonephritis only late in life, litters of B6 lpr/Irak-m-/-mice could be bred along Mendelian ratios from B6 lpr/Irak-m+/-mice and revealed no weight gain differences compared with B6 mice (data not shown). For SLE phenotype analysis we fi rst evaluated IRAK-M mRNA expression in spleens of B6 lpr mice and found IRAK-M mRNA to be increasingly expressed over time (data not shown).
Next we compared the size of spleens and lymph nodes in 6-month-old B6 lpr and B6 lpr/Irak-m-/-mice. The spleens and lymph nodes were signifi cantly enlarged in B6 lpr/Irak-m-/-mice compared with B6 lpr mice ( fi gure 1B ). This was evident from spleen and bulk lymph node weights. Spleen histomorphology in 6-monthold mice showed that B6 lpr/Irak-m-/-mice had lymph follicle hyperplasia with an expansion of T cell and CD11c+ dendritic cell areas while CD19+ B cell areas were similar to those of B6 lpr mice, also evidenced by a quantitative assessment of stained spleen scans ( fi gure 1C ). Thus, lack of IRAK-M accelerates lymphoproliferation in mice when introduced in the context of a single additional lupus susceptibility gene ( lpr ).
IRAK-M suppresses the activation of dendritic cells in B6 lpr mice
IRAK-M modulates pathogen recognition in monocyte/ macrophages, 21 23 2A ) . This was associated with increased mRNA levels of IL-6 and IL-12 and with the IFNα-dependent genes Mx1, Ifi t1, TLR7 and TLR9 in the CD11b+ splenocyte population ( fi gure 2B ). By contrast, IfNβ mRNA was not detectable in Irak-m -defi cient B6 lpr mice (not shown). Plasma cell differentiation and survival factors Baff/ BlyS and Bcl2 33 were also induced in Irak-m -defi cient CD11b+ splenocytes ( fi gure 2B ). Consistent with increased dendritic cell activation, B6 lpr/Irak-m-/-mice had higher serum levels of IL-12 than B6 lpr mice ( fi gure 2C ). Thus, in autoimmune B6 lpr mice, IRAK-M suppresses dendritic cell activation-that is, their production of proinfl ammatory cytokines and factors that promote the differentiation of B cells into plasma cells and plasma cell survival.
IRAK-M suppresses T cell expansion and stabilises the potential of regulatory T cells to suppress T cells in B6 lpr mice
Given its impact on dendritic cell activation, lack of IRAK-M might affect T cell populations in B6 lpr mice. Consistent with the expansion of spleen T cell areas ( fi gure 1B ), the numbers of CD4+ and CD8+ T cells, CD4/CD8 double negative 'autoreactive' T cells and CD4+/CD25+/Foxp3 'regulatory' T cells were all increased in the spleens of Irak-m -defi cient B6 lpr mice and expressed higher levels of the activation marker CD69 ( fi gure 3A ). The latter was consistent with increased FoxP3 mRNA expression in CD4/CD25+ T cells ( fi gure 3B ). IRAK-M defi ciency-associated expansion of CD4 T cells did not affect the Th1/Th2 balance as the mRNA expression of Th1 markers (T-bet/IFNγ) and Th2 markers (GATA3/IL-4) were consistently induced in these cells in B6 lpr/Irak-m-/-compared with B6 lpr mice ( fi gure 3B ). Th17 cells and IL-17 mRNA expression were undetectable in mice of both genotypes. How does the expansion of Tregs affect T cell proliferation in Irak-m -defi cient B6 lpr mice? To answer this question we performed a T cell suppression assay by co-culturing CD4+CD25+, CD4+CD25 neg and APC derived from spleens of either lpr or Irak-m -defi cient B6 lpr mice. In both strains the same proportion of CD4+CD25+ cells stained positive for FoxP3 (data not shown). Interestingly, however, a signifi cantly decreased level of Treg-induced suppression was observed in cells derived from Irak-m-defi cient B6 lpr mice (data not shown). To determine whether the loss of suppression is due to non-functional Tregs in Irak-m-defi cient B6 lpr mice, we co-cultured Tregs derived from this strain with wild-type APC. Strikingly, Irak-m-defi cient Tregs showed clearly reduced suppression even in co-culture with wild-type APC or vice versa, Irak-m -defi cient B6 lpr mice developed more hypergammaglobulinaemia than B6 lpr wild-type mice, which was not signifi cant group.bmj.com on November 24, 2014 -Published by http://ard.bmj.com/ Downloaded from before 6 months of age and mostly affected the IgG 2c and IgG 3 isotypes (data not shown). At that time, lack of IRAK-M had also increased the serum dsDNA autoantibody levels from all IgG isotypes ( fi gure 4A ). The specifi city of dsDNA autoantibodies was confi rmed by the Critidiae luciliae assay. Diluted serum from B6 lpr/Irak-m-/-mice showed a much more intense binding to the dsDNA of the fl agellate`s kinetoplast than serum of B6 lpr mice. In addition, lack of IRAK-M was associated with increased production of anti-Sm IgG, anti-SnRNP IgG and anti-nucleosome IgG from 5 months of age compared with B6 lpr mice ( fi gure 4B ). In contrast, rheumatoid factor levels were not affected by the Irak-m genotype ( fi gure 4B ). Lack of IRAK-M obviously accelerated autoantibody production of all isotypes, an effect that antedates the development of hypergammaglobulinaemia of only selected IgG isotypes by 1-2 months. Thus, IRAK-M preferentially suppresses the expansion of autoreactive plasma cells and the production of numerous autoantibodies against nuclear RNA and DNA autoantigens in B6 lpr mice.
IRAK-M protects B6 lpr mice from fatal autoimmune tissue injury
SLE may be associated with little or even fatal autoimmune tissue injury, 34 but B6 lpr mice do not develop major tissue lesions and only mild glomerulonephritis from 6 months of age. 8 Irakm-defi cient B6 lpr mice had signifi cant peribronchial mononuclear cell infi ltrates and pneumonitis ( fi gure 5A ) and a semiquantitative lung injury score of 2.6±0.1 for B6 lpr/Irak-m-/-mice compared with 0.3±0.2 for B6 lpr mice (p<0.0001). Furthermore, Irak-m defi ciency was associated with diffuse mesangioproliferative glomerulonephritis, as indicated by PAS-positive matrix expansion, glomerular hypercellularity and capillary obstruction ( fi gure 5B ). The composite activity score for lupus nephritis was 7.9±0. group.bmj.com on November 24, 2014 -Published by http://ard.bmj.com/ Downloaded from mice (p=0.0001). In Irak-m -defi cient B6 lpr mice, increased glomerular damage was associated with increased glomerular positivity for C3c (0.4±0.1 for B6 lpr mice vs 1.2±0.1 for B6 lpr/Irak-m-/-mice, p=0.0005). Does the genotype-dependent autoimmune tissue injury affect the mortality of B6 lpr mice? In Irak-m -defi cient B6 lpr mice, 50% had died at 34 weeks of age while none of the B6 lpr mice had died up to 52 weeks of age ( fi gure 5C ), suggesting that IRAK-M is a gene that protects B6lpr mice signifi cantly from SLE and from SLE-related mortality Together, IRAK-M protects B6 lpr mice from systemic autoimmunity and also from fatal autoimmune tissue injury, mainly by suppressing the activation of APC and the expansion of autoreactive lymphocytes.
IRAK-M suppresses autoimmunity by inhibiting TLR7 signalling in B6 lpr mice
The immunostimulatory effects of endogenous nucleic acids are known to drive SLE via TLR7. 35 36 We therefore speculated that Irak-m defi ciency aggravated murine lupus mainly by uncoupling TLR7 signalling. To test this concept we treated additional cohorts of B6 lpr and B6 lpr/Irak-m-/-mice with a TLR7 inhibitor. 28 29 All mice were treated for 10 weeks and killed at 6 months of age. TLR7 blockade abrogated the accelerated kidney and lung disease in Irak-m-defi cient B6 lpr mice to the phenotype level of B6 lpr mice ( fi gure 6A , B ). Most strikingly, none of the Irak-mdefi cient B6 lpr mice treated with TLR7 antagonist died during the study period; hence, TLR7 blockade prevented the premature lethality observed in Irak-m-defi cient B6 lpr mice. In contrast, TLR7 antagonism had only a minor and non-signifi cant effect on the mild SLE phenotype of B6 lpr mice ( fi gure 6 ). TLR7 blockade completely reversed the expansion of spleen T cells including the CD4/CD8-negative 'autoreactive' T cells ( fi gure 6C ). TLR7 blockade also reversed the increased levels of RNA (but not DNA) autoantibodies in Irak-m-defi cient B6 lpr mice ( fi gure 6C , d ata not shown). We therefore conclude that Irak-m defi ciency accelerates SLE in B6 lpr mice by fostering TLR7 signalling.
DISCUSSION
TLR7 signalling contributes to autoimmunity 6 35 and IRAK-M suppresses TLR signalling, 21 so we hypothesised that IRAK-M might suppress autoimmunity. Our data support the latter by two lines of evidence. First, Irak-m defi ciency aggravates the autoimmune phenotype and mortality of B6 lpr mice. Second, TLR7 blockade almost entirely abrogates the aggravated autoimmune phenotype of Irak-m-defi cient B6 lpr mice.
We selected B6 lpr mice as an appropriate latent autoimmunity model because female B6 lpr mice develop some lupus autoantibodies but no major autoimmune tissue injuries. 8 The selection of lpr mice on the C57BL/6 genetic background also allowed us to intercross them with Irak-m -defi cient B6 mice to obtain and expand B6 lpr/Irak-m-/-mice. Introducing Irak-m defi ciency into B6 lpr mice introduced premature mortality in these mice by dramatically accelerating their autoimmune phenotype in terms of autoantibody production and autoimmune tissue injury, both of which were earlier in onset and more severe at a given time point. As Irak-m defi ciency alone did not cause autoimmunity in B6 mice, IRAK-M instead acts as a modifi er or enhancer gene together with the lpr mutation. Obviously the Fas defi ciency provided by the lpr mutation is suffi cient for loss of tolerance (ie, autoimmunity), but overt autoimmune disease requires at least another single genetic abnormality such as dysfunctional Irak-m in B6 lpr mice. These data are in line with studies that introduced Tlr9 or Sigirr defi ciency into B6 lpr mice. 16 17 It is noteworthy that Tlr9 or Sigirr defi ciency both accelerate autoimmunity in lupus mice by enhancing TLR7 signalling in APC. 17 36 37 For SIGIRR, these fi ndings were also validated in pristane-induced lupus of B6 mice. 38 TLR7 signalling was recently found to contribute signifi cantly to lupus-like autoimmunity because ribonucleoproteins such as U1snRNP act as endogenous TLR7 agonists and activate dendritic cells and B cells such as viral RNA. 39 -41 As such, TLR7 signalling induces type I interferons and interferonstimulated genes and enhances autoantigen presentation which fosters autoantigen-directed T and B cell responses (ie, autoimmunity). 6 42 Our comparative phenotype analysis of B6 lpr and B6 lpr/Irak-m-/-mice showed that all of these aforementioned components were also associated with the B6 lpr/Irak-m-/-genotype. Because TLR7 antagonism almost entirely prevented the aggravated autoimmune phenotype of B6 lpr/Irak-m-/-mice, we conclude that Irak-m defi ciency accelerates autoimmunity by uncoupling TLR7 signalling. Only the increased DNA autoantibody production was TLR7-independent and should relate to enhanced TLR9 signalling. 16 While the specifi city of the TLR7 antagonist used in this study is under debate, 43 its lack of modulating DNA autoantibodies adds to the evidence for its specifi city by in vitro testing. 28 IRAK-M has been shown to suppress TLR4 signalling by preventing the dissociation of IRAK1 and IRAK4 from the TLR/ MyD88 signalling complex as an essential element of the TLR downstream signalling cascade towards the activation of MAP kinases and NF-κB. 21 TLR7 (and TLR9) use the identical MyD88-dependent signalling pathway, 32 which is consistent with our fi nding that Irak-m -defi cient spleen monocytes display increased TNFα or IL-6 production on stimulation with TLR4, TLR7 or TLR9 agonists or other studies that observed increased TLR2 and TLR7 signalling on Irak-m silencing in RAM macrophages. 44 A suppressive role of IRAK-M on autoimmune tissue injury is also anticipated by a recent study that found IRAK-M induction to be associated with repeated TLR7 agonist exposure which ultimately suppressed experimental allergic encephalomyelitis in mice. 45 In summary, lack of IRAK-M accelerates autoimmunity and autoimmune tissue injury of B6 lpr mice by enhancing TLR7-dependent pathomechanisms. Suppression of autoimmunity is a previously unknown function of IRAK-M. We identifi ed loss of function mutations in the IRAK-M gene that are previously unknown genetic risk factors for SLE and potentially also for other systemic autoimmune diseases.
